Jiewen Peng

发表

Entecavir vs lamivudine for prevention of hepatitis B virus reactivation among patients with untreated diffuse large B-cell lymphoma receiving R-CHOP chemotherapy: a randomized clinical trial.

Tongyu Lin, Jun Zhu, S. Ye, 2014, JAMA.

Gemcitabine plus cisplatin versus fluorouracil plus cisplatin in recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 trial

Jianji Pan, Xiaozhong Chen, Rensheng Wang, 2016, The Lancet.

Gemcitabine Plus Cisplatin Versus Fluorouracil Plus Cisplatin as First-Line Therapy for Recurrent or Metastatic Nasopharyngeal Carcinoma: Final Overall Survival Analysis of GEM20110714 Phase III Study

Jianji Pan, Xiaozhong Chen, Rensheng Wang, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized, Multicenter Study of Gefitinib Dose-escalation in Advanced Non-small-cell Lung Cancer Patients Achieved Stable Disease after One-month Gefitinib Treatment

W. Feng, J. Jia, Li Zhang, 2015, Scientific Reports.

A single-arm, multicenter, safety-monitoring, phase IV study of icotinib in treating advanced non-small cell lung cancer (NSCLC).

B. Han, Yiping Zhang, Shucai Zhang, 2014, Lung cancer.

Rituximab plus chemotherapy as first-line treatment in Chinese patients with diffuse large B-cell lymphoma in routine practice: a prospective, multicentre, non-interventional study

Wei Li, R. Feng, Yongping Song, 2016, BMC Cancer.

Three-year Follow-up on the Safety and Effectiveness of Rituximab Plus Chemotherapy as First-Line Treatment of Diffuse Large B-Cell Lymphoma and Follicular Lymphoma in Real-World Clinical Settings in China: A Prospective, Multicenter, Noninterventional Study

Changping Wu, Wei Li, R. Feng, 2018, Chinese medical journal.

[Expression of secreted frizzled-related protein 4 in DNA mismatch repair-deficient and mismatch repair-proficient colorectal cancers].

Yanfang Zheng, Kexu Chen, Hanlin Liang, 2018, Nan fang yi ke da xue xue bao = Journal of Southern Medical University.

Dose-Dense Rituximab-CHOP versus Standard Rituximab-CHOP in Newly Diagnosed Chinese Patients with Diffuse Large B-Cell Lymphoma: A Randomized, Multicenter, Open-Label Phase 3 Trial

Chengcheng Guo, Wenyu Li, H. Hong, 2018, Cancer research and treatment : official journal of Korean Cancer Association.

Prognostic value of androgen receptor expression in operable triple-negative breast cancer: a retrospective analysis based on a tissue microarray

Zhongyu Yuan, Jie-hua He, R. Peng, 2012, Medical Oncology.

Classical CMF regimen as adjuvant chemotherapy for triple-negative breast cancer may be more effective compared with anthracycline or taxane-based regimens

Zhongyu Yuan, R. Peng, Yanxia Shi, 2012, Medical Oncology.

RESEARCH ARTICLE Hepatitis B Virus Infection Is Associated with Poor Prognosis in Patients with Advanced Non Small Cell Lung Cancer

Jianning Xiao, G. Lin, Z. Xia, 2015 .

Programmed Cell Death-1 Polymorphisms Decrease the Cancer Risk: A Meta-Analysis Involving Twelve Case-Control Studies

Mancheng Gong, Wenjing Dong, Junkai Zhang, 2016, PloS one.

LncRNA HOTAIR promotes proliferation, invasion and migration in NSCLC cells via the CCL22 signaling pathway

Hanlin Liang, Jiewen Peng, 2022, PloS one.

Rituximab plus chemotherapy as first-line treatment in Chinese patients with diffuse large B-cell lymphoma in routine practice: a prospective, multicentre, non-interventional study

Changping Wu, Wei Li, R. Feng, 2016, BMC Cancer.

Safety and efficacy results of a phase IV, open-label, multicenter, safety-monitoring study of icotinib in treating advanced non-small cell lung cancer (NSCLC): ISAFE study.

Yiping Zhang, Shucai Zhang, K. Ying, 2013 .